I Think the Immunosuppression Era Just Ended — And the Pharma Industry Should Be Terrified
CAR-T cell therapy has crossed from oncology into autoimmune medicine and produced something lifelong lupus patients were told would never exist — durable drug-free remission inside twenty-four weeks of a single infusion. The Zorpo-cel CASTLE trial in Nature Medicine (January 2026, twenty-four patients across systemic lupus, systemic sclerosis, and myositis) achieved ninety percent DORIS remission in its lupus arm, and the Erlangen cohort's longest-treated patient now stands five years drug-free while the Müller NEJM 2024 extension of fifteen patients held remission through twenty-nine months of median follow-up. Independent Chinese cohorts under Wang, Feng, and an allogeneic CD19 program add another forty-three patients to the replication pile across a different continent and different manufacturing processes. Beneath that clinical convergence sits a brutal economic and ethical reality — ex vivo infusions currently list between four hundred thousand and six hundred fifty thousand US dollars, and roughly ninety percent of the world's three to five million lupus patients live in countries where no reimbursement pathway exists. The year 2026 marks the credible beginning of immunosuppression's retirement as the default treatment philosophy in severe autoimmune disease. The real story is not the science itself but the fight — now just beginning — over who gets to participate in it.